Team creates realistic 3-D tumour through tissue engineering using silk scaffolds

June 20, 2013, National University of Singapore

A team of NUS researchers from the Departments of Bioengineering and Orthopaedic Surgery has developed a highly realistic three-dimensional (3-D) tumour model. As it replicates the conditions in the body, it is able to track the effectiveness and progress of drug therapy. Their model has the potential to be a more effective method for studying tumours than in-vitro and even in-vivo methods.

The team comprised Professor James Goh, Associate Professor Toh Siew Lok and Dr Pamela Tan from the Department of Bioengineering at NUS Faculty of Engineering, and Associate Professor Saminathan Suresh Nathan from the Department of Orthopaedic Surgery at the NUS Yong Loo Lin School of Medicine, who carried out their study using , which is the most prevalent form of paediatric primary .

Reconstructing tumours in the laboratory has been a hot topic for research as current methods of testing have not been sufficient to yield concrete results.

Dr Tan, who has been researching on the 3-D model for her PhD thesis, said: "Despite the urgent need to develop , little progress has been made due to the lack of good pre-clinical drug testing models. Current laboratory drug testing methods yield results that differ largely from because of the use of 2-D cell culture systems which cannot replicate the 3-D properties of the ."

In in-vitro testing, cell culture systems are largely 2-D, hence, lack the structural features of the 3-D microenvironment. On the other hand, it is not feasible to carry out large-scale molecular biology research using in-vivo experiments. Furthermore, society has become increasingly concerned about the use of animals in experimentation.

Prof Goh said that , a major focus of study at the Department of , can help bridge these gaps, thereby establishing a more physiological 3-D in-vitro model. The team made use of techniques from tissue engineering to fabricate the 3-D tumour model and reconstructed the tumour tissue into factors and cell types in order to form a clinically relevant tumour.

The team decided to use silk to fabricate the scaffolds onto which the osteosarcoma cells were grown because it has been demonstrated to have excellent properties for cell attachment and growth.

Their 3-D tumour construct gives results that are much closer to those obtained from in-vivo studies, as compared to 2-D in-vitro studies. When chemotherapeutic drugs (which target aggressively growing cells) were tested on the 3-D tumour constructs, their effectiveness in killing cancer cells was greatly reduced, compared to testing the same drugs using the standard 2-D system. Moreover, the therapeutic doses found using the 3-D tumour constructs was within those measured in mice, indicating that the constructs have the potential to help bridge the gap between laboratory and animal testing, in order to improve the yield and quality of chemotherapeutic drug screening.

This is also the first time that a realistic 3-D tumour has been constructed in a laboratory using silk scaffolds in a pressurised bioreactor. Their 3-D bioreactor tumour model was able to express markers that indicate the ability of a tumour to initiate blood vessel growth at levels almost identical to that of the mouse model. The tumour constructs also responded to drugs that prevent blood vessel formation in a manner similar to that observed clinically.

"Our also makes it possible to study how tumour cells interact with cells of the surrounding tissue, which results in more aggressive tumour behaviour," added Dr Tan.

The team has been developing the concept of the tumour microenvironment as an important determinant of tumour behaviour over the last 10 years.

Said Assoc Prof Nathan, "Dr Tan's recent contribution has shed remarkable insight into mechanisms of angiogenesis that were previously taken for granted and may now have to be re-addressed. Clinically this will have significant bearing on other drugs as well."

"We will in future be expanding our findings to other cancers and incorporating other aspects of the tumour like oxygen levels within the system to ultimately create a platform for testing that could save much in downstream applications of experimental drugs," he added.

Explore further: Nanotechnology helps track and improve drug action in pancreatic cancer

Related Stories

Nanotechnology helps track and improve drug action in pancreatic cancer

June 12, 2013
(Medical Xpress)—UK and Australian scientists have been able to show ways in which we can markedly improve drug targeting of solid tumours, using tiny 'biosensors' along with new advanced imaging techniques.

Immune system to fight brain tumors

May 30, 2013
Research at Lund University in Sweden gives hope that one of the most serious types of brain tumour, glioblastoma multiforme, could be fought by the patients' own immune system. The tumours are difficult to remove with surgery ...

Brain tumour cells killed by anti-nausea drug

March 18, 2013
(Medical Xpress)—New research from the University of Adelaide has shown for the first time that the growth of brain tumours can be halted by a drug currently being used to help patients recover from the side effects of ...

Discovering a new role for a breast cancer gene

January 18, 2013
(Medical Xpress)—Researchers at the School of Biosciences have identified an unexpected role for a tumour-associated gene in breast cancer.

Scientists develop simple blood test to track tumour evolution in cancer patients

May 3, 2013
By tracking changes in patients' blood, Cambridge scientists have created a new way of looking at how tumours evolve in real-time and develop drug resistance. The research was published in the print edition of Nature today.

New possibilities for prostate cancer treatment revealed

May 29, 2013
Researchers have identified a sub-group of cells that could contribute to prostate cancer recurrence, opening up new ways to treat the disease, which claims more than 3000 lives a year in Australia.

Recommended for you

Single blood test screens for eight cancer types

January 18, 2018
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.